STAA

STAAR Surgical Co. (STAA) - Form 8-K Summary

Business Context and Reporting Period

Date of Report: August 4, 2025
Company: STAAR Surgical Company (Delaware corporation)
Event: Entry into a Material Definitive Agreement (Merger Agreement) with Alcon Research, LLC ("Alcon").
Structure: Alcon's wholly-owned subsidiary, Rascasse Merger Sub, Inc., will merge with and into STAAR Surgical, with STAAR surviving as a wholly-owned subsidiary of Alcon.

Key Financial Metrics and Transaction Terms

Merger Consideration: $28.00 in cash per share of STAAR common stock, without interest.
Termination Fees:

• STAAR to Alcon: $43.4 million (reduced to $14.5 million if triggered by a "qualified bidder" superior proposal).
• Alcon to STAAR: $72.4 million (payable if terminated due to failure to obtain required regulatory approvals).

Financial Performance: The filing does not provide current revenue, profit, cash flow, or margin data. Investors should refer to the Company's 10-K for the year ended December 27, 2024, for historical financials.

Material Changes and Conditions

Board Action: The Board unanimously approved the Merger Agreement, determined it is fair and in the best interests of stockholders, and resolved to recommend adoption.
Conditions to Closing:

• Adoption of the Merger Agreement by STAAR stockholders.
• Receipt of requisite regulatory approvals (including HSR Act waiting period expiration).
• Absence of laws or orders prohibiting the Merger.
• No Material Adverse Effect on the Company.

Delisting: Upon closing, STAAR common stock will be delisted from NASDAQ and deregistered under the Securities Exchange Act of 1934.

Outlook, Risks, and Management Commentary

Timeline: The Merger must be completed by August 4, 2026 ("End Date"), subject to a potential three-month extension if regulatory approvals are delayed.
Superior Proposals: STAAR is restricted from soliciting alternative proposals but may terminate the agreement to accept a superior proposal (subject to payment of termination fees).
Risks:

• Failure to obtain stockholder or regulatory approval.
• Disruption of business operations and retention of key personnel.
• Potential decline in stock price if the transaction is not consummated.
• Legal proceedings related to the transaction.

Management Commentary: Management urges stockholders to read the upcoming Proxy Statement (Schedule 14A) before voting, as it will contain detailed information regarding the transaction.

Investor Verification Checklist

• Proxy Statement (Schedule 14A): Verify the final terms, voting procedures, and detailed financial analysis once filed.
• Regulatory Status: Monitor the status of Hart-Scott-Rodino (HSR) and other international regulatory approvals.
• Stockholder Vote: Confirm the date, time, and location of the special stockholder meeting to be announced.
• Termination Fee Triggers: Review the specific definitions of "qualified bidder" and "superior proposal" in the full Merger Agreement (Exhibit 2.1).
• Historical Financials: Review the 10-K filed on February 21, 2025, for the most recent audited financial data.